Is Cibus Global LLC (CBUS) overvalued? · rev $4.3M
Cibus Global LLC (CBUS) is a biotechnology company listed on US.
This page asks whether Cibus Global LLC (CBUS) looks expensive on cached numbers — not a short thesis.
Latest reported CBUS revenue for 2024-12-31 was $4.3M. Net income was -$282.7M. Revenue was up 134.6% from 2023-12-31 to 2024-12-31. CBUS currently screens at market cap $79.7M.
CBUS currently screens at market cap $79.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CBUS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CBUS stock page for the full model, not this heading.
Not investment advice.